Key Takeaways from Agenus' Earnings Report (AGEN)

Key Takeaways from Agenus' Earnings Report

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Click Here Now

Shares of biotech Agenus (Nasdaq: AGEN ) appreciated almost 5% today, after the company posted its 3rd quarter earnings. The company's key compound, QS-21 Stimulon, is licensed to some of the biggest players in the pharmaceutical space, ,including GlaxoSmithKline (NYSE: GSK ) and Janssen, which is a subsidiary of Johnson & Johnson (NYSE: JNJ ) .

In the following video, health care analysts Max Macaluso and David Williamson discuss the company's latest quarter and a few things Agenus investors should watch.

Biotech companies can be some of the most exciting-and riskiest-investments on the market. However, it's essential to balance speculative plays in your portfolio with stocks that can help you build long-term weatlh. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you retire well, and also include some winning wealth-building strategies that every investor should know. Click here now to keep reading.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

Max Macaluso, Ph.D. and David Williamson have no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying calls on Johnson & Johnson. The Motley Fool has a disclosure policy.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.